Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

SMX Strengthens Balance Sheet and Eliminates Corporate-Level Convertible Indebtedness

Full conversion of convertible notes reduces long-term liabilities, removes potential equity overhang, and helps ...

Teva Pharmaceutical Industries Ltd: Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...
The Next

For Seton Hall’s Savannah Catalon, leadership goes beyond the box score

Since arriving in South Orange for the 2023-24 season, Seton Hall guard Savannah Catalon has been an impact player and leader ...